Evidence map›Paper›PMID 26647301›Full record

ArticleArchives of toxicology2016

A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis.

L Smirnova, G Harris, J Delp, M Valadares, D Pamies, H T Hogberg, T Waldmann, M Leist, T Hartung

Abstract readEvaluation Study
In one paragraph

Article in Archives of toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Research models to study lewy body dementia.Molecular neurodegeneration · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L SmirnovaCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA. lsmirno1@jhu.edu.
G HarrisCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
J DelpCenter for Alternatives to Animal Testing (CAAT), Department of Biology, University of Konstanz, Konstanz, Germany.
M ValadaresCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
D PamiesCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
H T HogbergCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
T WaldmannCenter for Alternatives to Animal Testing (CAAT), Department of Biology, University of Konstanz, Konstanz, Germany.
M LeistCenter for Alternatives to Animal Testing (CAAT), Department of Biology, University of Konstanz, Konstanz, Germany.
T HartungCenter for Alternatives to Animal Testing (CAAT), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.

Funding

A 3D Model of Human Brain Development for Studying Gene/Environment InteractionsU18TR000547 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HARTUNG, THOMAS · 2012 to 2013
$865k
Developmental neurotoxicity pathways for high throughput testing by metabolomicsU01FD004230 · FDA · JOHNS HOPKINS UNIVERSITY · PI HARTUNG, THOMAS · 2011 to 2012
$815k
FDA HHS U01 FD004230NCATS NIH HHS U18 TR000547
6 · The paper itself

Abstract

Several shortcomings of current Parkinson's disease (PD) models limit progress in identification of environmental contributions to disease pathogenesis. The conditionally immortalized cell line LUHMES promises to make human dopaminergic neuronal cultures more easily available, but these cells are difficult to culture for extended periods of time. We overcame this problem by culturing them in 3D with minor medium modifications. The 3D neuronal aggregates allowed penetration by small molecules and sufficient oxygen and nutrient supply for survival of the innermost cells. Using confocal microscopy, gene expression, and flow cytometry, we characterized the 3D model and observed a highly reproducible differentiation process. Visualization and quantification of neurites in aggregates was achieved by adding 2 % red fluorescent protein-transfected LUHMES cells. The mitochondrial toxicants and established experimental PD agents, rotenone and MPP

Indexed as

Antiparkinson AgentsCell AggregationCell Culture TechniquesCell DifferentiationCell Line, TransformedCell SurvivalDopaminergic NeuronsDrug Evaluation, PreclinicalDrug ResistanceGene Expression RegulationHumansImaging, Three-DimensionalLuminescent ProteinsMicroscopy, ConfocalMicroscopy, FluorescenceNerve Tissue ProteinsAntiparkinson AgentsLuminescent ProteinsNerve Tissue ProteinsNeuroprotective AgentsNeurotoxinsRecombinant Proteins3D culturemicroRNANeurotoxicityResilienceRotenone

Identifiers

PMID26647301
PMCPMC5065586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.